KRAS mutations, which are present in approximately 90% of PC cases, drive tumor progression through constitutive MAPK/ERK and PI3K/AKT signaling, influencing the TME and promoting tumor stemness 33,34. This evidence concerns the gene KRAS and neoplasm.